BriaCell Reports 'Dramatic' Anti-tumor Response in Breast Cancer Patient in Phase 2 Study; Shares Up Pre-Bell

MT Newswires Live10-01

BriaCell Therapeutics (BCTX) said Tuesday that a breast cancer patient treated in a phase 2 study of the company's Bria-IMT regimen showed a "dramatic anti-tumor response."

The company said treatment with its Bria-IMT regimen resulted in complete resolution of right temporal lobe brain metastasis in the patient with "eye-bulging" metastatic breast cancer.

The patient showed an initial partial response at two months in the brain lesion without a detectable disease after eight and 11 months of treatment, the company said.

The patient, who continues to receive treatment with the Bria-IMT regimen, had failed eight previous regimens including antibody-drug conjugate therapy, BriaCell said.

BriaCell shares were up almost 17% in premarket activity on Tuesday.

Price: 1.4499, Change: +0.21, Percent Change: +16.93

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472332727?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-01 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2472332727","market":"hk","top_or_hot":-1,"title":"BriaCell Reports 'Dramatic' Anti-tumor Response in Breast Cancer Patient in Phase 2 Study; Shares Up Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> BriaCell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BCTX) said Tuesday that a breast cancer patient treated in a phase 2 study of the company's Bria-IMT regimen showed a \"dramatic anti-tumor response.\"</p><p>The company said treatment with its Bria-IMT regimen resulted in complete resolution of right temporal lobe brain metastasis in the patient with \"eye-bulging\" metastatic breast cancer.</p><p>The patient showed an initial partial response at two months in the brain lesion without a detectable disease after eight and 11 months of treatment, the company said.</p><p>The patient, who continues to receive treatment with the Bria-IMT regimen, had failed eight previous regimens including antibody-drug conjugate therapy, BriaCell said.</p><p>BriaCell shares were up almost 17% in premarket activity on Tuesday.</p><p>Price: 1.4499, Change: +0.21, Percent Change: +16.93</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BriaCell Reports 'Dramatic' Anti-tumor Response in Breast Cancer Patient in Phase 2 Study; Shares Up Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBriaCell Reports 'Dramatic' Anti-tumor Response in Breast Cancer Patient in Phase 2 Study; Shares Up Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-01 20:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BriaCell Therapeutics (BCTX) said Tuesday that a breast cancer patient treated in a phase 2 study of the company's Bria-IMT regimen showed a \"dramatic anti-tumor response.\"The company said treatment ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2472332727","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472332727","pubTimestamp":1727786785,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BriaCell Therapeutics  said Tuesday that a breast cancer patient treated in a phase 2 study of the company's Bria-IMT regimen showed a \"dramatic anti-tumor response.\"The company said treatment with its Bria-IMT regimen resulted in complete resolution of right temporal lobe brain metastasis in the patient with \"eye-bulging\" metastatic breast cancer.The patient showed an initial partial response at two months in the brain lesion without a detectable disease after eight and 11 months of treatment, the company said.The patient, who continues to receive treatment with the Bria-IMT regimen, had failed eight previous regimens including antibody-drug conjugate therapy, BriaCell said.BriaCell shares were up almost 17% in premarket activity on Tuesday.Price: 1.4499, Change: +0.21, Percent Change: +16.93","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BCTX":"BriaCell Therapeutics Corp."},"translate_title":"BriaCell在2期研究中报告了乳腺癌患者的“显著”抗肿瘤反应；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCTX":0.9},"content_text":"BriaCell Therapeutics (BCTX) said Tuesday that a breast cancer patient treated in a phase 2 study of the company's Bria-IMT regimen showed a \"dramatic anti-tumor response.\"The company said treatment with its Bria-IMT regimen resulted in complete resolution of right temporal lobe brain metastasis in the patient with \"eye-bulging\" metastatic breast cancer.The patient showed an initial partial response at two months in the brain lesion without a detectable disease after eight and 11 months of treatment, the company said.The patient, who continues to receive treatment with the Bria-IMT regimen, had failed eight previous regimens including antibody-drug conjugate therapy, BriaCell said.BriaCell shares were up almost 17% in premarket activity on Tuesday.Price: 1.4499, Change: +0.21, Percent Change: +16.93","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472332727"}